Replies to post #14909 on GTC Biotherapeutics (fka GTCB)

[OKY]

DEW, they make it sound like GTC rejected LEO, Am I dreaming
again. Should this news have been considered positive?

"...In previous calls we have indicated that the patient recruitment into the phase II study in DIC, being run by LEO, has been slower than planned. Following an internal strategic review and reprioritization by LEO, GTC has entered into negotiations for the transition of the program for commercialization and clinical development for Europe and the Middle East from LEO Pharma to LFB. LEO has confirmed that there are no safety or efficacy issues with the ATryn® product, either commercially or in the phase II DIC clinical study. LFB, currently a 20% shareholder in GTC, has expressed a significant interest in commercializing ATryn® for its approved indications in Europe ..."

Or is this just more spin

[gym gravity]

"The CD137 antibody continues with preclinical studies and we are preparing for a pre-IND meeting with the FDA."

I couldn't find a timeline for cd-137 in the rmf... what are your thoughts?